{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:15:37Z","timestamp":1790709337371,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jacc.2025.03.454","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T08:10:02Z","timestamp":1742199002000},"page":"1943-1955","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis With Cardiomyopathy"],"prefix":"10.1016","volume":"85","author":[{"given":"Farooq H.","family":"Sheikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3899-9983","authenticated-orcid":false,"given":"Gilbert","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8335-735X","authenticated-orcid":false,"given":"W.H. Wilson","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D.","family":"Gillmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9606-1347","authenticated-orcid":false,"given":"Ugochukwu O.","family":"Egolum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Longhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongshu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Aldinc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-2078","authenticated-orcid":false,"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jacc.2025.03.454_bib1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","article-title":"Evolving landscape in the management of transthyretin amyloidosis","volume":"47","author":"Hawkins","year":"2015","journal-title":"Ann Med"},{"issue":"22","key":"10.1016\/j.jacc.2025.03.454_bib2","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacc.2025.03.454_bib3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jacc.2025.03.454_bib4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/13506129.2014.964858","article-title":"Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis","volume":"21","author":"Sipe","year":"2014","journal-title":"Amyloid"},{"issue":"8","key":"10.1016\/j.jacc.2025.03.454_bib5","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1212\/WNL.0000000000001870","article-title":"Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study","volume":"85","author":"Adams","year":"2015","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jacc.2025.03.454_bib6","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"issue":"9","key":"10.1016\/j.jacc.2025.03.454_bib7","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/ejhf.2606","article-title":"Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis","volume":"24","author":"Chacko","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.jacc.2025.03.454_bib8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10741-014-9462-7","article-title":"Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs","volume":"20","author":"Castano","year":"2015","journal-title":"Heart Fail Rev"},{"issue":"2","key":"10.1016\/j.jacc.2025.03.454_bib9","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS)","volume":"164","author":"Ruberg","year":"2012","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.jacc.2025.03.454_bib10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacc.2025.03.454_bib11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jacc.2024.04.011","article-title":"Prognostic value of a 6-minute walk test in patients with transthyretin cardiac amyloidosis","volume":"84","author":"Ioannou","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.jacc.2025.03.454_bib12","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2023-0158","article-title":"Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature review","volume":"13","author":"Nativi-Nicolau","year":"2024","journal-title":"J Comp Eff Res"},{"issue":"5","key":"10.1016\/j.jacc.2025.03.454_bib13","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.cardfail.2022.10.423","article-title":"Minimal clinically important differences in 6-minute walk test in patients with HFrEF and iron deficiency","volume":"29","author":"Khan","year":"2023","journal-title":"J Card Fail"},{"issue":"3","key":"10.1016\/j.jacc.2025.03.454_bib14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamacardio.2022.5251","article-title":"Association of tafamidis with health status in patients with ATTR cardiac amyloidosis: a post hoc analysis of the ATTR-ACT randomized clinical trial","volume":"8","author":"Sperry","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"20","key":"10.1016\/j.jacc.2025.03.454_bib15","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","article-title":"Interpreting the Kansas City cardiomyopathy questionnaire in clinical trials and clinical care: JACC state-of-the-art review","volume":"76","author":"Spertus","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacc.2025.03.454_bib16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jacc.2025.03.454_bib17","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City cardiomyopathy questionnaire: a new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.03.454_bib18","unstructured":"Berk JL, Drachman B, Lairez O, et al. Decline in functional capacity is associated with reduced ability to perform activities of daily living in patients with transthyretin cardiac amyloidosis: post hoc analysis of the APOLLO-B study. Poster presented at: Heart Failure Congress; May 11-14, 2024; Lisbon, Portugal."},{"issue":"3","key":"10.1016\/j.jacc.2025.03.454_bib19","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1183\/09031936.00140507","article-title":"Interpretation of treatment changes in 6-minute walk distance in patients with COPD","volume":"32","author":"Puhan","year":"2008","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.jacc.2025.03.454_bib20","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ahj.2004.12.010","article-title":"Monitoring clinical changes in patients with heart failure: a comparison of methods","volume":"150","author":"Spertus","year":"2005","journal-title":"Am Heart J"},{"issue":"15","key":"10.1016\/j.jacc.2025.03.454_bib21","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1161\/CIRCULATIONAHA.106.670901","article-title":"Identifying heart failure patients at high risk for near-term cardiovascular events with serial health status assessments","volume":"115","author":"Kosiborod","year":"2007","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.jacc.2025.03.454_bib22","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1001\/jamacardio.2017.3983","article-title":"Association of serial Kansas City cardiomyopathy questionnaire assessments with death and hospitalization in patients with heart failure with preserved and reduced ejection fraction: a secondary analysis of 2 randomized clinical trials","volume":"2","author":"Pokharel","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"6","key":"10.1016\/j.jacc.2025.03.454_bib23","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/ejhf.1810","article-title":"Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction","volume":"22","author":"Butler","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.jacc.2025.03.454_bib25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10741-020-10010-8","article-title":"Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges","volume":"26","author":"Bruno","year":"2021","journal-title":"Heart Fail Rev"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725057961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725057961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T02:22:06Z","timestamp":1762309326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725057961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":24,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0735109725057961"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.03.454","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis With Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.03.454","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}